绥美凯（多替阿巴拉米片）用法用量

On January 22, 2018, (Dolutea Paramide Tablets) was launched in China and is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40 kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B5701 allele, he should not take products containing abacavir. Since the advent of the first anti-HIV drug zidovudine (AZT) in 1987, it has brought life hope to AIDS patients. Subsequently, more and more drugs have continued to appear, with more and more types of drugs, better and better therapeutic effects, and fewer and fewer side effects. At present, the world has basically entered the era of integrase inhibitor drugs, and continues to introduce new ones in the optimization of multi-drug combination regimens. Today we will learn about the usage and dosage of Suimeikai (Doteta Abalamid Tablets).

Trimax (dolute abalamib tablets) is suitable for adults and adolescents over 12 years old and weighing no less than 40kg. Since the ingredients in Trimax (dolute abalamic tablets) may cause hypersensitivity reactions, regardless of the patient's race, patients should be screened for HLA-B*5701 alleles before starting treatment with abacavir-containing products.  

The recommended dosage of Suimeike (Dolutea Paramid Tablets) is one tablet, once daily. Adults or adolescents whose weight is less than 40kg should not be given Trimax (dolute abalamib tablets) because Trimax is a fixed-dose tablet and the dose cannot be reduced. Reducing the dose without authorization may result in ineffectiveness of the drug. Clinical data on Trimax (dolutegravir tablets) are limited. The most commonly reported adverse reactions that are possibly or probably related to dolutegravir and abacaramvir/lamivudine are nausea (12%), insomnia (7%), dizziness (6%) and headache (6%).

Pediatric Use: The safety and effectiveness of Suimeike (Dolutea Paramil Tablets) in children under 12 years of age has not been established. No data yet. Use in Geriatric Patients: There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients 65 years and older. There is no evidence that older patients require different dosages than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when using Suimika in this age group.

The above is the usage and dosage of (Dolte Abalamid Tablets), I hope it can help you!